Celeste Santoro

Comparison of real-world data (RWD) analysis on efficacy and post-progression outcomes with pembrolizumab plus chemo vs chemo alone in metastatic non-squamous non-small cell lung cancer with PD-L1 < 50%

F. de Marinis, A. Passaro, G. Antonarelli, 2022, Frontiers in Oncology.

Tumor Infiltrating Lymphocytes across Breast Cancer Subtypes: Current Issues for Biomarker Assessment

G. Curigliano, D. Trapani, G. Antonarelli, 2023, Cancers.